Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lab4P probiotic
- Development stage
- Unknown
- Lead developer
- Cultech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lab4P probiotic is a proprietary multi-strain live biotherapeutic product consisting of five specific bacterial strains: Lactobacillus acidophilus CUL60, Lactobacillus acidophilus CUL21, Bifidobacterium bifidum CUL20, Bifidobacterium animalis subsp. lactis CUL34, and Lactobacillus plantarum CUL66. Developed by Cultech in the UK, this consortium is designed to survive stomach acidity and bile and has been clinically studied for its effects on weight management (notably supporting weight loss), cardiovascular health (including cholesterol modulation and anti-atherogenic effects), immune support (anti-inflammatory actions via reduction of cytokines such as IL-6 and TNF-α), digestive health (improving bowel habits), and potential neuroprotective benefits. The mechanism of action involves modulation of gut microbiota composition leading to metabolic improvements—such as reduced LDL/VLDL cholesterol levels—and immunomodulation through decreased pro-inflammatory cytokine production[1][5][6][8][9][10].
- Brand names
- ProVen Probiotics 50 Billion ShapelineLaxabiota (as a component)Lab4P probioticLab-4P probioticLab 4P probiotic
- Other names
- Lab4P consortiumLab-4P consortiumLab 4P consortiumLab4P blendLab-4P blendLab 4P blendLab4P complexLab-4P complexLab 4P complex
Beyond the preview
Go deeper on Lab4P probiotic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lab4P probiotic.